Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease
Arch Neurol 62:1242-1248, Avorn,J.,et al, 2005
Camptocormia
Neurol 65:355-359, Azher,S.N. &Jankovic,J., 2005
Initial Diagnoses Given to Persons with the Fragile X Associated Tremor/Ataxia Syndrome (FXTAS)
Neurol 65:299-301, Hall,D.A.,et al, 2005
Update on Primary Central Nervous System Lymphoma
Curr Opin Neurol 18:645-653, Plotkin,S.R., 2005
Clinicopath Conf., Primary Diffuse Large-B-Cell Lymphoma of the Brain
NEJM 352:185-194, Case 1-2005, 2005
Migraine-Anxiety Related Dizziness (MARD): A New Disorder?
JNNP 76:1-8, Furman,J.M.,et al, 2005
The role of radiotracer imaging in Parkinson disease
Neurol 64:208-215, Ravina, B., et al, 2005
Amorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease
Neurol 64:392-393, Pot, C., et al, 2005
Quantatative Assessment of Driving Performance in Parkinson's Disease
JNNP 76:176-180, 159, Wood, J.M., et al, 2005
Genetic Screening for a Single Common LRRK2 Mutation in Familial Parkinson's Disease
Lancet 365:410-412, Nichols, W.C., et al, 2005
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Clinicopath Conf, Human Granulocytic Ehrlichiosis
NEJM 352:1358-1364, Case 10-2005, 2005
Pallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Arch Neurol 62:554-560,533, Anderson,V.C.,et al, 2005
Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005
Short-Term Paroxetine Treatment Does Not Alter the Motor Response to Levodopa in PD
Neurol 64:1797-1798, Chung,K.A.,et al, 2005
[99mTc]TRODAT-1 SPECT Imaging Correlates with Odor Identification in Early Parkinson Disease
Neurol 64:1716-1720, Siderowf,A.,et al, 2005
Clinicopath Conf, Prion Disease (Sporadic Creutzfeldt-Jakob Disease)
NEJM 353:1042-1050, Case 27-2005, 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Science and Ethics of Sham Surgery, A Survey of Parkinson Disease Clinical Researchers
Arch Neurol 62:1357-1360,1343, Kim,S.Y.H.,et al, 2005
Neurologic Spectrum of Chronic Liver Failure and Basal Ganglia T1 Hyperintensity on Magnetic Resonance Imaging, Probably Manganese Neurotoxicity
Arch Neurol 62:1385-1390, Klos,K.J.,et al, 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Neuropathology of Dementia in Parkinsons Disease: A Prospective, Community-Based Study
Ann Neurol 58:773-776,663, Aarsland,D.,et al, 2005
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Arch Neurol 62:1595-1600, Omuro,A.M.P.,et al, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Occupation and Parkinsonism in Three Movement Disorders Clinics
Neurol 65:1430-1435, Goldman,S.M.,et al, 2005
Excessive Daytime Sleepiness and Subsequent Development of Parkinson Disease
Neurol 65:1442-1446, Abbott,R.D.,et al, 2005
Levodopa Addiction in Idiopathic Parkinson Disease
Neurol 65:1508, Borek,L.L &Friedman,J.H., 2005
Modafinil for Daytime Somnolence in Parkinsons Disease: Double Blind, Placebo Controlled Parallel Trial
JNNP 76:1636-1639, Ondo,W.G.,et al, 2005
Late-Onset Friedreich Ataxia
Arch Neurol 62:1865-1869, Bhidayasiri,R.,et al, 2005
MRI Detection of Cysts of the Knee Causing Common Peroneal Neuropathy
Neurol 65:1829-1831, Iverson,D.J., 2005
A Double-blind Placebo-controlled Trial of Botulinum Toxin B for Sialorrhea in Parkinson's Disease
Neurol 62:37-40, Ondo,W.G.,et al, 2004
The Parkinsonian Phenotype of Spinocerebellar Ataxia Type 2
Arch Neurol 61:35-38, Lu,C.,et al, 2004
Treatment-Induced Leukoencephalopathy in Primary CNS Lymphoma,A Clinical and Autopsy Study
Neurol 62:451-456, Lai,R.,et al, 2004
Penetrance of the Fragile X-Associated Tremor/Ataxia Syndrome in a Premutation Carrier Population
JAMA 291:460-469, Jacquemont,S.,et al, 2004
Neuroprotection in Parkinson Disease, Mysteries, Myths, and Misconceptions
JAMA 291:358-364, Schapira,A.H.V.&Olanow,C.W., 2004
Ophthalmologic Features of Parkinson's Disease
Neurol 62:177-180, Biousse,V.,et al, 2004
Effect of Levodopa Treatment for Parkinsonism in Welders
Neurol 62:730-733, Koller,W.C.,et al, 2004
Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Parkinson's Disease
Lancet 363:1783-1793, Samii,A.,et al, 2004
Methylprednisolone, Valacyclovir, or the Combination for Vestibular Neuritis
NEJM 351:354-361,322, Strupp,M.,et al, 2004
Basal Ganglia Hyperperfusion in a Patient with Systemic Lupus Erythematosus-Related Parkinsonism
Neurol 63:395-396, Lee,P.H.,et al, 2004
Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004
Idiopathic Hyposmia As a Preclinical Sign of Parkinson's Disease
Ann Neurol 56:173-181,169, Ponsen,M.M.,et al, 2004
Surgical and Hardware Complications of Subthalamic Stimulation
Neurol 63:612-616, Lyons,K.E.,et al, 2004
Pathogenetic Mechanisms of Parkin in Parkinson's Disease
Lancet 364:722-724, Hattori,N. &Mizuno,Y., 2004
Clinicopath Conf, Multiple-System Atrophy
NEJM 351:912-921, Case 27-2004, 2004
Monoamine Oxide Type B Inhibitors in Early Parkinson's Disease:Meta-Analysis of 17 Randomised Trials Involving 3525 Patients
BMJ 329:593-596, Ives,N.J.,et al, 2004